Cosmos Health Inc. has secured a cumulative orderbook of over 25 million units through its wholly owned subsidiary Cana Laboratories S.A., positioning the contract manufacturing division to generate over $10 million in recurring annual profit at full capacity. The agreements span multiple partners and nine therapeutic categories, with contract terms extending up to 10 years, providing long-term cash flow visibility and reducing dependence on any single product or partner.

Cana operates a 54,000 sq. ft., EU-GMP-licensed, EMA-certified facility in Athens. The company has invested approximately $5.5 million in upgrading the facility, including the installation of a new ACG capsule-filling line, to expand its capabilities. The orderbook includes diverse formats such as vials, packs, bottles, capsules, and pessaries, covering central nervous system, musculoskeletal, dermatological, vitamin, anti-inflammatory, oncology-support, women’s health, antiseptic, and wellness categories.

Contract Manufacturing Orderbook

The following table details the key agreements secured by Cana Laboratories:

Strategic Impact

Cosmos Health views contract manufacturing as a high-margin, recurring-revenue segment central to its vertically integrated model. By leveraging its EU-licensed facility to serve third-party partners, the company aims to maximize utilization, spread fixed costs, and generate incremental revenue while maintaining control over the quality and supply of its own proprietary brands. With current agreements using only a portion of available capacity, the company continues to pursue additional contracts and evaluate further expansion.

CosmoFarm S.A., a wholly owned subsidiary of Cosmos Health Inc., delivered record revenue of over $15 million in the second quarter of 2026, representing an annualized run-rate of over $60 million. The subsidiary added more than 80 new pharmacies to its distribution network during the period, solidifying its position as a leading pharmaceutical wholesaler in the greater Athens area. To support this accelerating growth, Cosmos Health is increasing capital expenditure at CosmoFarm, investing in new robotic automation and artificial intelligence systems to enhance procurement, inventory management, and order fulfillment.

Expansion and Automation Investments

Cosmos Health is expanding the size of the CosmoFarm facility to accommodate higher volumes and continued network expansion. These investments build on CosmoFarm's existing automated infrastructure, including ROWA and SSI SCHÄFER A-frame robotic systems. The company stated that these systems have driven improvements in operational efficiency, unit economics, and profitability per customer.

Key Performance Indicators

Management Commentary

Greg Siokas, CEO of Cosmos Health, stated that CosmoFarm's record second quarter marks an important milestone, with revenue reaching an annualized run-rate of over $60 million. He noted that the addition of over 80 new pharmacies reflects the strength of the company's distribution platform and the trust of its growing customer base. Siokas further emphasized that by investing further in robotic automation, artificial intelligence, and expanded facility capacity, the company is positioning CosmoFarm to sustain this momentum, improve margins, and continue scaling profitably.